Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Am J Trop Med Hyg. 2011 Sep;85(3):573-8. doi: 10.4269/ajtmh.2011.11-0250.
We evaluated the efficacy and effectiveness of mefloquine (MQ) plus artesunate (AS) to treat patients with uncomplicated malaria in the Peruvian Amazon Basin in April 2005-March 2006. Patients ≥ 1 year of age with fever (axillary temperature ≥ 37.5°C) or history of fever and Plasmodium falciparum monoinfection were included. Patients received antimalarial treatment with MQ (12.5 mg/kg/day for two days) and AS (4.0 mg/kg/day for three days) either by directly observed therapy or without directly observed therapy. After a 28-day follow-up, treatment efficacy and effectiveness were assessed on the basis of clinical and parasitologic outcomes. Ninety-six patients were enrolled in each study group; nine patients were lost to follow-up. All patients, except for one in the observed group, demonstrated adequate clinical and parasitologic response; none had detectable parasitemia on day 3. The efficacy of MQ + AS efficacy was 98.9% (95% confidence interval = 94.1-100.0%) and the effectiveness was 100.0% (95% confidence interval = 95.9-100.0%). Our study shows that MQ + AS is highly efficacious in the Peruvian Amazon.
我们评估了甲氟喹(MQ)加青蒿琥酯(AS)治疗 2005 年 4 月至 2006 年 3 月秘鲁亚马逊流域无并发症疟疾患者的疗效和效果。纳入标准为年龄≥ 1 岁、发热(腋温≥37.5°C)或有发热史且为恶性疟原虫单一感染的患者。患者接受 MQ(12.5mg/kg/天,连用两天)和 AS(4.0mg/kg/天,连用三天)治疗,包括直接观察治疗或非直接观察治疗。在 28 天随访后,根据临床和寄生虫学结果评估治疗效果和效果。每组 96 例患者入组,9 例患者失访。除观察组的 1 例患者外,所有患者均表现出充分的临床和寄生虫学应答,第 3 天均无寄生虫血症。MQ+AS 的疗效为 98.9%(95%置信区间为 94.1-100.0%),效果为 100.0%(95%置信区间为 95.9-100.0%)。我们的研究表明,MQ+AS 在秘鲁亚马逊地区具有很高的疗效。